Protagonist Therapeutics, Inc (PTGX)

Etorro trading 970x250
Protagonist Therapeutics, Inc (PTGX) Logo

About Protagonist Therapeutics, Inc

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn’s disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase II clinical trial for treating inflammatory bowel disease (IBD). The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn’s disease and ulcerative colitis; and PN-235 and PN-232 oral interleukin-23 receptor antagonist candidates for IBD and non-IBD indications. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. Address: 7707 Gateway Boulevard, Newark, CA, United States, 94560-1160

Protagonist Therapeutics, Inc News and around…

Latest news about Protagonist Therapeutics, Inc (PTGX) common stock and company :

Noteworthy Tuesday Option Activity: SONO, QGEN, PTGX
17 Nov, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sonos Inc (SONO), where a total of 15,005 contracts have traded so far, representing approximately 1.5 million underlying shares. That amounts to about 63.7% of SONO's average daily trading volume over the past month of 2.4 million shares..

What 9 Analyst Ratings Have To Say About Protagonist Therapeutics
15 Nov, 2021 FinancialContent

Over the past 3 months, 9 analysts have published their opinion on Protagonist Therapeutics (NASDAQ:PTGX) stock. These analysts are ...

Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis
15 Nov, 2021 Yahoo! Finance

Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced results from a Phase 2a study in which rusfertide, an investigational new drug, is being evaluated for the treatment of hereditary hemochromatosis (HH). HH is a genetic disorder arising from a deficiency or dysregulation of the natural hormone hepcidin, a condition which causes the body to absorb too much iron. The clinical data from the study were presented in an oral presentation at The Liver Meeting® of t

Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
11 Nov, 2021 Yahoo! Finance

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present and host one-on-one meetings with investors at upcoming healthcare investor conferences hosted by Jefferies and Piper Sandler.

Protagonist Therapeutics Trying To Close In On Key Technical Benchmark
11 Nov, 2021 FinancialContent

A Relative Strength Rating upgrade for Protagonist Therapeutics shows improving technical performance. Will it continue?

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
08 Nov, 2021 FinancialContent

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good ...

Why Protagonist Therapeutics Stock Skyrocketed 80.2% Last Month
08 Nov, 2021 FinancialContent

Following huge swings over the last two months, the biotech stock is now up 67% year to date.

Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Polycythemia Vera Selected for Oral Presentations at the ASH 2021 Annual Meeting
04 Nov, 2021 Yahoo! Finance

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that two abstracts highlighting updated data from its Phase 2 study of rusfertide in polycythemia vera (PV) have been selected for oral presentations at the American Society of Hematology (ASH) 2021 Annual Meeting taking place December 11-14, 2021. An additional three abstracts on rusfertide in PV and hereditary hemochromatosis (HH) have been accepted as poster presentations at ASH.

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
03 Nov, 2021 Yahoo! Finance

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -4.48% and 199.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Protagonist Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
03 Nov, 2021 Yahoo! Finance

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported its financial results for the third quarter ended September 30, 2021 and provided a corporate update.

5 Short Squeeze Candidates To Watch: Progenity Tops List Again, Augmented Reality Play WiMi Hologram Joins List
01 Nov, 2021 FinancialContent

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) or AMC ...

Analysts Estimate Protagonist Therapeutics (PTGX) to Report a Decline in Earnings: What to Look Out for
27 Oct, 2021 Yahoo! Finance

Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Protagonist Therapeutics Earns $7.5 Million Milestone Payment from IL-23 Receptor Collaboration with Janssen
26 Oct, 2021 Yahoo! Finance

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that it will receive a $7.5 million milestone payment from Janssen Biotech, Inc. (Janssen) triggered by the completion of the clinical data collection-related Phase 1 activities for PN-235 (JNJ-2113). This investigational drug candidate is one of the three IL-23 receptor antagonists that are part of Protagonist's collaboration agreement with Janssen, which provides for concurrent development of multipl

Short Squeeze Stocks: PTGX, AGC and 3 Others Experts Think Are Ready to Pop
25 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Here are five short squeeze stocks many investors are putting on their radar right now as a result of higher short interest and borrow fees. The post Short Squeeze Stocks: PTGX, AGC and 3 Others Experts Think Are Ready to Pop appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

5 Short Squeeze Candidates To Watch: Progenity, Digital Brands Top List Again, SPAC AGC Joins Ahead Of Merger
25 Oct, 2021 FinancialContent

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) or AMC ...

The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
22 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating ...

How The Pieces Add Up: SMMV Headed For $43
20 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $43.03 per unit.

The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
18 Oct, 2021 FinancialContent

Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market ...

Hedge Funds Are Crazy About Protagonist Therapeutics, Inc. (PTGX)
18 Oct, 2021 Yahoo! Finance

At Insider Monkey, we pore over the filings of nearly 873 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we’ve gathered as a result gives us access to a wealth of collective knowledge based on these firms’ portfolio holdings as of June 30th. In this […]

Ten stocks worth watching next week
16 Oct, 2021 FinancialContent
New Strong Sell Stocks for October 14th
14 Oct, 2021 Yahoo! Finance

ARNC, BSET, FMS, OCUL, and PTGX have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2021.

J.P. Morgan Says There’s Room for Over 40% Upside in These 2 Stocks
14 Oct, 2021 Yahoo! Finance

Stuck for fresh investing inspiration? You’re not alone. Plenty of uncertainty lingers on Wall Street as we head into 2022. Inflation is up, the job market remains stuck in an ugly combination of stubborn unemployment and record-high levels of job openings, all while Congress and the Biden Administration are looking less and less capable of passing a set of aggressive spending plans. Writing from JPMorgan, global market strategist Marko Kolanovic acknowledges the headwinds but thinks there are p

What 10 Analyst Ratings Have To Say About Protagonist Therapeutics
13 Oct, 2021 FinancialContent

Analysts have provided the following ratings for Protagonist Therapeutics (NASDAQ:PTGX) within the last quarter: ...

10 Biggest Price Target Changes For Wednesday
13 Oct, 2021 FinancialContent

MKM Partners raised the price target on Continental Resources, Inc. (NYSE: CLR) from $47 to $54. Continental Resources shares fell ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Oct, 2021 FinancialContent

Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares rose 26.55% to $8.58 during Tuesday's regular session. NRX Pharmaceuticals's stock ...

Analyst Ratings For Protagonist Therapeutics
12 Oct, 2021 FinancialContent

Analysts have provided the following ratings for Protagonist Therapeutics (NASDAQ:PTGX) within the last quarter: ...

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021
12 Oct, 2021 FinancialContent

Upgrades For Callaway Golf Co (NYSE:ELY), Compass Point upgraded the previous rating of Neutral to Buy. Callaway Golf earned $0.36 in ...

10 Biggest Price Target Changes For Tuesday
12 Oct, 2021 FinancialContent

Evercore ISI Group raised Lear Corporation (NYSE: LEA) price target from $170 to $220. Lear shares fell 0.3% to close at ...

Protagonist Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit
12 Oct, 2021 Yahoo! Finance

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer and Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology will participate in a fireside chat at the upcoming Jefferies Next Generation IBD Therapeutics Summit taking place virtually on October 19, 2021.

46 Biggest Movers From Yesterday
12 Oct, 2021 FinancialContent

Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares jumped 93.9% to close at $35.36 on Monday. The FDA removed the full ...

Protagonist Therapeutics, Inc (PTGX) is a NASDAQ Common Stock listed in , ,

970x250